Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial.
- Additional Document Info
- View All
BACKGROUND: Treatment decision-making regarding immunosuppressive therapy is challenging for individuals with lupus. We assessed the effectiveness of a decision aid for immunosuppressive therapy in lupus nephritis. METHODS AND FINDINGS: In a United States multicenter, open-label, randomized controlled trial (RCT), adult women with lupus nephritis, mostly from racial/ethnic minority backgrounds with low socioeconomic status (SES), seen in in- or outpatient settings, were randomized to an individualized, culturally tailored, computerized decision aid versus American College of Rheumatology (ACR) lupus pamphlet (1:1 ratio), using computer-generated randomization. We hypothesized that the co-primary outcomes of decisional conflict and informed choice regarding immunosuppressive medications would improve more in the decision aid group. Of 301 randomized women, 298 were analyzed; 47% were African-American, 26% Hispanic, and 15% white. Mean age (standard deviation [SD]) was 37 (12) years, 57% had annual income of <$40,000, and 36% had a high school education or less. Compared with the provision of the ACR lupus pamphlet (n = 147), participants randomized to the decision aid (n = 151) had (1) a clinically meaningful and statistically significant reduction in decisional conflict, 21.8 (standard error [SE], 2.5) versus 12.7 (SE, 2.0; p = 0.005) and (2) no difference in informed choice in the main analysis, 41% versus 31% (p = 0.08), but clinically meaningful and statistically significant difference in sensitivity analysis (net values for immunosuppressives positive [in favor] versus negative [against]), 50% versus 35% (p = 0.006). Unresolved decisional conflict was lower in the decision aid versus pamphlet groups, 22% versus 44% (p < 0.001). Significantly more patients in the decision aid versus pamphlet group rated information to be excellent for understanding lupus nephritis (49% versus 33%), risk factors (43% versus 27%), medication options (50% versus 33%; p 0.003 for all); and the ease of use of materials was higher in the decision aid versus pamphlet groups (51% versus 38%; p = 0.006). Key study limitations were the exclusion of men, short follow-up, and the lack of clinical outcomes, including medication adherence. CONCLUSIONS: An individualized decision aid was more effective than usual care in reducing decisional conflict for choice of immunosuppressive medications in women with lupus nephritis. TRIAL REGISTRATION: Clinicaltrials.gov, NCT02319525.
author list (cited authors)
Singh, J. A., Fraenkel, L., Green, C., Alarcn, G. S., Barton, J. L., Saag, K. G., ... Yazdany, J.
complete list of authors
Singh, Jasvinder A||Fraenkel, Liana||Green, Candace||Alarcón, Graciela S||Barton, Jennifer L||Saag, Kenneth G||Hanrahan, Leslie M||Raymond, Sandra C||Kimberly, Robert P||Leong, Amye L||Reyes, Elyse||Street, Richard L||Suarez-Almazor, Maria E||Eakin, Guy S||Marrow, Laura||Morgan, Charity J||Caro, Brennda||Sloan, Jeffrey A||Jandali, Bochra||Garcia, Salvador R||Grossman, Jennifer||Winthrop, Kevin L||Trupin, Laura||Dall'Era, Maria||Meara, Alexa||Rizvi, Tara||Chatham, W Winn||Yazdany, Jinoos
editor list (cited editors)